Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
PatientsLikeMe was bought by UnitedHealth following a review by Trump's Treasury Department, which scrutinized the start-up because it's backed by Chinese cash.Technologyread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
An Air Canada passenger traveling to Toronto from a weekend in Quebec City found herself stranded alone on the tarmac and in the dark, in what she described as a "nightmare."Airlinesread more
When Victoria's Secret exited the swimsuit business in 2016, it opened the floodgates for start-ups to conquer that market.Retailread more
U.K. online bank Monzo raised $144 million in a fresh round of funding led by the U.S. start-up accelerator Y Combinator.Technologyread more
A medication used to treat hypothyroidism has been voluntarily recalled due to quality concerns.
Westminster Pharmaceuticals, LLC has instructed wholesalers to stop distributing specific products labeled "Levothyroxine and Liothyronine (Thyroid Tablets, USP)," according to an August 9 release. Levothyroxine and Liothyronine are synthetic hormones contained in the thyroid tablets.
The voluntary national recall alert says there have been no "adverse events" associated with the recalled products. It says patients should continue taking the drugs.
More from USA Today:
Oatmeal, breakfast foods contain unsafe amounts of cancer-linked weed killer
Is this drug the most promising development on Alzheimer's in recent history?
FDA expands recall of heart drug for possible cancer-causing contamination
"Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product," the release says.
More than 4.5 percent of the U.S. population over the age of 12 suffers from an underactive thyroid or hypothyroidism, according to the National Library of Medicine's MedlinePlus.
The release instructs patients to speak with their physician before discontinuing use of the medicine.
The recall follows a June 22 warning letter from the Food & Drug Administration to a Chinese pharmaceutical company which manufactured active ingredients in the recalled drug. The letter cited a number of failures, including ones relating to "established standards of quality and purity."
The recall alert says issues cited in that warning letter "could represent the possibility of risk being introduced into the manufacturing process."
A full list of recalled products is available from the FDA.
Patients with questions or information about an issue relating to the recalled products can contact Westminster at: 888-354-9939.